U.S. Stock Insider Trading | Cerus Disclosed Three Insider Transactions on March 10

K-LinePoet · 2026-03-25T20:43:21+00:00

Cerus Company disclosed insider trading activity by executive Benjamin Richard J on March 10, 2026. He sold over 100,000 shares during the period of March 5-9. Cerus is a biopharmaceutical company focused on enhancing blood safety.

K-LinePoet

2026-03-25 20:43:21

Abstract generation in progress

On March 10, 2026, Cerus (CERS) disclosed three insider trading transactions. Executive Benjamin Richard J sold 61,200 shares on March 9, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 10, 2026	Executive	Benjamin Richard J	March 9, 2026	Sell	40,400	1.88	76,000
March 10, 2026	Executive	Benjamin Richard J	March 6, 2026	Sell	24,200	2.01	48,600
March 10, 2026	Executive	Benjamin Richard J	March 5, 2026	Sell	61,200	2.06	126,300
March 9, 2026	Executive	Jensen Chrystal	March 6, 2026	Sell	30,800	2.01	61,900
March 9, 2026	Executive	Green Kevin Dennis	March 6, 2026	Sell	27,800	2.01	55,700
March 9, 2026	Executive	Jayaraman Vivek K	March 6, 2026	Sell	34,100	2.01	68,400
March 9, 2026	Executive	Green Kevin Dennis	March 5, 2026	Sell	55,200	2.06	113,900
March 9, 2026	Director	Greenman William Mariner	March 6, 2026	Sell	78,200	2.01	156,800
November 26, 2025	Executive	Jensen Chrystal	November 24, 2025	Sell	55,000	1.70	93,500
August 25, 2025	Director	Gregory Dean A.	August 25, 2025	Buy	25,000	1.25	31,300

[Company Profile]

Cerus Corporation, founded in California in 1991 and reincorporated in Delaware in 1996, is a biopharmaceutical company focused on developing and commercializing the INTERCEPT blood system to enhance blood safety. The company’s INTERCEPT blood system is designed to work with blood components and certain derivatives: platelets, plasma, red blood cells, and to produce INTERCEPT fibrinogen complexes (IFC), as well as pathogen-reduced plasma and cryoprecipitate.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.